An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease.

OBJECTIVE This study assessed the employer cost burden of predialysis CKD-related anemia for a major US manufacturer, by examining indirect and direct costs before and after initiation of epoetin alfa (EPO). METHODS Hemoglobin (Hb) levels, direct costs, and indirect costs for employees with CKD-related anemia were collected for 15 months (9 months pre-EPO… (More)